The DOI matches its Crossref record.
The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.
Abstract
We examined the antigenic and functional characteristics of human peripheral blood lymphocytes that differentially express the CD16 (Leu-11) and Leu-19 (NKH-1) antigens. Leu-19 is a approximately 220,000 daltons protein expressed on approximately 15% of freshly isolated peripheral blood lymphocytes. Within the Leu-19+ subset, three distinct populations were identified: CD3-,CD16+,Leu-19+ cells; CD3+,CD16-,Leu-19+ cells; and CD3-,CD16-,Leu-19bright+ cells. Both the CD3+,CD16-,Leu-19+ and CD3-,CD16+,Leu-19+ populations mediated non-major histocompatibility complex (MHC)-restricted cytotoxicity against the NK-sensitive tumor cell K562 and were large granular lymphocytes. CD3-,CD16+,Leu-19+ NK cells were the most abundant (comprising approximately 10% of peripheral blood lymphocytes) and the most efficient cytotoxic effectors. The finding that CD3+,Leu 19+ lymphocytes mediated cytotoxicity against K562 unequivocally demonstrates that a unique subset of non-MHC-restricted cytotoxic CD3+ T lymphocytes are present in the peripheral blood of unprimed, normal individuals. However, CD3+,CD16-,Leu-19+ cells comprised less than 5% of peripheral blood lymphocytes, and the cytotoxic activity of this subset was significantly less than CD3-,CD16+,Leu-19+ NK cells. Most CD3+,Leu-19+ T cells co-expressed the CD2, CD8, and CD5 differentiation antigens. The antigenic and functional phenotype of peripheral blood CD3+,Leu-19+ cytotoxic T lymphocytes corresponds to the interleukin 2-dependent CD3+ cell lines that mediate non-MHC-restricted cytotoxicity against NK-sensitive tumor cell targets. A small population of Leu-19bright+ lymphocytes lacking both CD3 and CD16 was also observed. This population (comprising less than 2% of peripheral blood lymphocytes) contained both large agranular lymphocytes and large granular lymphocytes. CD3-,CD16-,Leu-19bright+ lymphocytes also mediate non-MHC-restricted cytotoxicity. The relationship of these CD3-CD16-,Leu-19bright+ lymphocytes to CD3+ T cells or CD16+ NK cells is unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Self-citationHuman natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur, T., Carson, W. E., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.10.3146 · Cited by 1,449
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Satoh-Takayama, N., Vosshenrich, C. A. J., Lesjean-Pottier, S., Sawa, S., Lochner, M., Rattis, F., Mention, J.-J., Thiam, K., Cerf-Bensussan, N., Mandelboim, O., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.11.001 · Cited by 1,095
Biology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
Regulation of human NK-cell cytokine and chemokine production by target cell recognition
Fauriat, C., Long, E. O., Ljunggren, H.-G., & Bryceson, Y. T. (2010) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 891
Spits, H., & Di Santo, J. P. (2011) · Nature Immunology · doi:10.1038/ni.1962 · Cited by 842
Lopez-Vergès, S., Milush, J. M., Schwartz, B. S., Pando, M. J., Jarjoura, J., York, V. A., Houchins, J. P., Miller, S., Kang, S.-M., Norris, P. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110900108 · Cited by 822
Self-citationMaturation of mouse NK cells is a 4-stage developmental program
Chiossone, L., Chaix, J., Fuseri, N., Roth, C., Vivier, E., & Walzer, T. (2009) · Blood · doi:10.1182/blood-2008-10-187179 · Cited by 787
Lopez-Vergès, S., Milush, J. M., Pandey, S., York, V. A., Arakawa-Hoyt, J., Pircher, H., Norris, P. J., Nixon, D. F., & Lanier, L. L. (2010) · Blood · doi:10.1182/blood-2010-04-282301 · Cited by 752
Self-citationThe Broad Spectrum of Human Natural Killer Cell Diversity
Freud, A. G., Mundy-Bosse, B. L., Yu, J., & Caligiuri, M. A. (2017) · Immunity · doi:10.1016/j.immuni.2017.10.008 · Cited by 695
Phillips, J. H., & Lanier, L. L. (1986) · The Journal of experimental medicine · doi:10.1084/jem.164.3.814 · Cited by 684
Self-citationEndocrine regulation of menstruation
Jabbour, H. N., Kelly, R. W., Fraser, H. M., & Critchley, H. O. D. (2006) · Endocrine Reviews · doi:10.1210/er.2004-0021 · Cited by 588
p46, a Novel Natural Killer Cell–specific Surface Molecule That Mediates Cell Activation
Sivori, S., Vitale, M., Morelli, L., Sanseverino, L., Augugliaro, R., Bottino, C., Moretta, L., & Moretta, A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1129 · Cited by 554
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
Ndhlovu, L. C., Lopez-Vergès, S., Barbour, J. D., Jones, R. B., Jha, A. R., Long, B. R., Schoeffler, E. C., Fujita, T., Nixon, D. F., & Lanier, L. L. (2012) · Blood · doi:10.1182/blood-2011-11-392951 · Cited by 514
Self-citationFawzy, F. I. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810200037005 · Cited by 503
Human natural killer cell development
Freud, A. G., & Caligiuri, M. A. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00451.x · Cited by 497
Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule.
Lanier, L. L., Testi, R., Bindl, J., & Phillips, J. H. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.6.2233 · Cited by 494
Self-citationWhat does it take to make a natural killer?
Colucci, F., Caligiuri, M. A., & Di Santo, J. P. (2003) · Nature Reviews Immunology · doi:10.1038/nri1088 · Cited by 493
Mrozek, E., Anderson, P., & Caligiuri, M. (1996) · Blood · doi:10.1182/blood.v87.7.2632.bloodjournal8772632 · Cited by 492
Crotta, S., Stilla, A., Wack, A., D'Andrea, A., Nuti, S., D'Oro, U., Mosca, M., Filliponi, F., Brunetto, R. M., Bonino, F., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011124 · Cited by 471
Peltanova, B., Raudenska, M., & Masarik, M. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0983-5 · Cited by 469
Vivier, E., Rebuffet, L., Narni-Mancinelli, E., Cornen, S., Igarashi, R. Y., & Fantin, V. R. (2024) · Nature · doi:10.1038/s41586-023-06945-1 · Cited by 467
Developmental pathways that generate natural-killer-cell diversity in mice and humans
Huntington, N. D., Vosshenrich, C. A. J., & Di Santo, J. P. (2007) · Nature Reviews Immunology · doi:10.1038/nri2154 · Cited by 461
Emerging insights into natural killer cells in human peripheral tissues
Björkström, N. K., Ljunggren, H.-G., & Michaëlsson, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.34 · Cited by 449
The IL-2 Receptor β Chain (p70): Role in Mediating Signals for LAK, NK, and Proliferative Activities
Siegel, J. P., Sharon, M., Smith, P. L., & Leonard, W. J. (1987) · Science · doi:10.1126/science.3116668 · Cited by 445
NK cells and type 1 innate lymphoid cells: partners in host defense
Spits, H., Bernink, J. H., & Lanier, L. (2016) · Nature Immunology · doi:10.1038/ni.3482 · Cited by 443
Self-citationA pan-cancer single-cell panorama of human natural killer cells
Tang, F., Li, J., Qi, L., Liu, D., Bo, Y., Qin, S., Miao, Y., Yu, K., Hou, W., Li, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.034 · Cited by 450
“In humans, NK cells can be subdivided into two major groups, CD56CD16 and CD56CD16, based on the expression levels of CD56 (NCAM1) and CD16 (FCGR3A).(9,10) The CD56CD16 NK cell population predominantly mediates the”
BackgroundPremature Ovarian Failure and Ovarian Autoimmunity*
Hoek, A., Schoemaker, J., & Drexhage, H. A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0291 · Cited by 439
Tissue Determinants of Human NK Cell Development, Function, and Residence
Dogra, P., Rancan, C., Ma, W., Toth, M., Senda, T., Carpenter, D. J., Kubota, M., Matsumoto, R., Thapa, P., Szabo, P. A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.022 · Cited by 439
Self-citationCaligiuri, M. A., Zmuidzinas, A., Manley, T. J., Levine, H., Smith, K. A., & Ritz, J. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1509 · Cited by 435
Cooper, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.012 · Cited by 434
Co-association of CD3ζ with a receptor (CD16) for IgG Fc on human natural killer cells
Lanier, L. L., Yu, G., & Phillips, J. H. (1989) · Nature · doi:10.1038/342803a0 · Cited by 432
Self-citationHidalgo, L. G., Sis, B., Sellares, J., Campbell, P. M., Mengel, M., Einecke, G., Chang, J., & Halloran, P. F. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03201.x · Cited by 428
Anegón, I., Cuturi, M. C., Trinchieri, G., & Perussia, B. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.2.452 · Cited by 368
Voehringer, D., Koschella, M., & Pircher, H. (2002) · Blood · doi:10.1182/blood-2002-02-0657 · Cited by 352
Visualizing the kinetics of tumor-cell clearance in living animals
Sweeney, T. J., Mailänder, V., Tucker, A. A., Olomu, A. B., Zhang, W., Cao, Y.-A., Negrin, R. S., & Contag, C. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12044 · Cited by 350
Single-cell chromatin modification profiling reveals increased epigenetic variations with aging
Cheung, P., Vallania, F., Warsinske, H. C., Donato, M., Schaffert, S., Chang, S. E., Dvorak, M., Dekker, C. L., Davis, M. M., Utz, P. J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.079 · Cited by 323
“The CD56dim subset, which accounts for approximately 90% of total NK cells, has stronger cytotoxic killer cell functions than the low-abundance CD56bright population (Lanier et al., 1986), whereas the latter is the major source of secreted cytokines (Cooper et al., 2001).”
Interleukin-2, Interleukin-15, and Their Roles in Human Natural Killer Cells
Becknell, B., & Caligiuri, M. A. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(04)86006-1 · Cited by 325
Metabolic Reprogramming Supports IFN-γ Production by CD56bright NK Cells
Keating, S. E., Zaiatz-Bittencourt, V., Loftus, R. M., Keane, C., Brennan, K., Finlay, D. K., & Gardiner, C. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501783 · Cited by 325
King, A., Wellings, V., Gardner, L., & Loke, Y. W. (1989) · Human Immunology · doi:10.1016/0198-8859(89)90060-8 · Cited by 321
Natural killer cells and cancer
Brittenden, J., Heys, S. D., Ross, J., & Eremin, O. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1226::aid-cncr2>3.0.co;2-g · Cited by 319
Van Camp, B., Durie, B., Spier, C., De Waele, M., Van Riet, I., Vela, E., Frutiger, Y., Richter, L., & Grogan, T. (1990) · Blood · doi:10.1182/blood.v76.2.377.377 · Cited by 307
Lymphocyte subset reference ranges in adult caucasians
Reichert, T., DeBruyère, M., Deneys, V., Tötterman, T., Lydyard, P., Yuksel, F., Chapel, H., Jewell, D., Van Hove, L., Linden, J., et al. (1991) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(91)90063-g · Cited by 301
Frey, M., Packianathan, N. B., Fehniger, T. A., Ross, M. E., Wang, W.-C., Stewart, C. C., Caligiuri, M. A., & Evans, S. S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.1.400 · Cited by 287
Steroid receptor expression in uterine natural killer cells
Henderson, T. A., Saunders, P. T. K., Moffett-King, A., Groome, N. P., & Critchley, H. O. D. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021174 · Cited by 283
CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells
Juelke, K., Killig, M., Luetke-Eversloh, M., Parente, E., Gruen, J., Morandi, B., Ferlazzo, G., Thiel, A., Schmitt-Knosalla, I., & Romagnani, C. (2010) · Blood · doi:10.1182/blood-2009-11-253286 · Cited by 286
Interleukin-2 and interleukin-15: immunotherapy for cancer
Fehniger, T. A., Cooper, M. A., & Caligiuri, M. A. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00021-1 · Cited by 280
The role of cytokines in the regulation of NK cells in the tumor environment
Konjević, G. M., Vuletić, A. M., Mirjačić Martinović, K. M., Larsen, A. K., & Jurišić, V. B. (2019) · Cytokine · doi:10.1016/j.cyto.2019.02.001 · Cited by 279
King, A., Balendran, N., Wooding, P., Carter, N. P., & Loke, Y. W. (1991) · Journal of Immunology Research · doi:10.1155/1991/83493 · Cited by 276
The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
Rezvani, K., & Rouce, R. H. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00578 · Cited by 272
Developmental and Functional Control of Natural Killer Cells by Cytokines
Wu, Y., Tian, Z., & Wei, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00930 · Cited by 269
On the nature and function of human uterine granular lymphocytes
King, A., & Loke, Y. W. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90014-k · Cited by 269
Koelle, D. M., Posavad, C. M., Barnum, G. R., Johnson, M. L., Frank, J. M., & Corey, L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1758 · Cited by 264
Zhang, J. Q., Nicoll, G., Jones, C., & Crocker, P. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002788200 · Cited by 229
Niwa, R., Sakurada, M., Kobayashi, Y., Uehara, A., Matsushima, K., Ueda, R., Nakamura, K., & Shitara, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2263 · Cited by 187
Metadata
- Authors
- Lanier, L. L., Le, A. M., Civin, C. I., Loken, M. R., & Phillips, J. H.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1986-06
- Volume
- 136
- Issue
- 12
- Pages
- 4480-4486
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1542501019
- Cited by
- 1,129
- References
- 0
- FWCI
- 19.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.